Patent · US Active

Dual function fibroblast growth factor 21 proteins

US9458214B2 · kind B2 · utility

8Cited by

3References

16Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Brian R. Boettcher · Winchester, US
Shari Lynn Caplan · Lunenburg, US
Douglas S. Daniels · Arlington, US
Norio Hamamatsu · Belmont, US
Stuart Licht · Cambridge, US
Stephen Craig Weldon · Leominster, US
Susan E. Cellitti · San Diego, US
Bernhard Hubert Geierstranger · Solana Beach, US
Andreas Loew · Somerville, US

Key dates

Filing date	Sep 25, 2012
Grant date	Oct 4, 2016
Priority date	—
Expiry date	Sep 25, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to dual function fusions proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.